Abstract:Ferroptosis of osteoblasts and endothelial cells was found in obesity‐related osteoporotic rat model, which was correlated with elevated serum TNF‐α level. Ferroptosis inhibitor administration could treat obesity‐related osteoporosis through rescuing impaired osteogenic‐angiogenic coupling and downregulating serum TNF‐α level. In vitro, TNF‐α could modulate susceptibility of human osteoblast‐like (MG63) and umbilical endothelial cells (HUVEC) to ferroptosis. Ferroptosis inhibitors could effectively suppress the cytotoxicity of TNF‐α on MG63 and HUVEC. The relationship of obesity and osteoporosis has been widely studied over the past years. However, the implications of obesity for bone health remain controversial, and the underlying molecular mechanism is not yet fully understood. This study demonstrated that high‐fat diet‐induced obesity leads to significantly decreased bone volume/tissue volume (BV/TV), trabecular number (Tb.N), and cortical thickness (Ct.Th) of male rat femur after mechanical loading effects of body weight were controlled. HFD‐induced obese rats exhibited attenuated expression of ferroptosis inhibitory protein SLC7A11 and GPX4 in bone tissues, which was correlated with elevated serum TNF‐α concentration. Ferroptosis inhibitor administration could effectively rescue decreased osteogenesis‐associated type H vessels and osteoprogenitors, and downregulate serum levels of TNF‐α to ameliorate bone loss in obese rats. Since ferroptosis and TNF‐α both affect bone and vessel formation, we further investigated the interaction between ferroptosis and TNF‐α, and its impact in osteogenesis and angiogenesis in vitro. In human osteoblast‐like MG63 and umbilical vein endothelial cells (HUVEC), TNF‐α/TNFR2 signaling promoted cystine uptake and GSH biosynthesis to provide protection against low‐dose ferroptosis inducer erastin. While, TNF‐α/TNFR1 facilitated ferroptosis in the presence of high‐dose erastin through ROS accumulation. Moreover, TNF‐α regulated ferroptosis‐induced osteogenic and angiogenic dysfunctions based on its ferroptosis regulatory role. Meanwhile, ferroptosis inhibitors could reduce intracellular ROS overproduction and enhance osteogenesis and angiogenesis in TNF‐α‐treated MG63 and HUVECs. This study revealed the interaction between ferroptosis and TNF‐α and its impact in osteogenesis and angiogenesis, which provides new insights into the pathogenesis and regenerative therapy of obesity‐related osteoporosis.

Ferroptosis increases obesity: Crosstalk between adipocytes and the neuroimmune system

Insight into the Role of Ferroptosis in Non-neoplastic Neurological Diseases

Iron Overload Protects from Obesity by Ferroptosis

Adipose Tissue Macrophage-Derived Exosomes Induce Ferroptosis Via Glutathione Synthesis Inhibition by Targeting SLC7A11 in Obesity-Induced Cardiac Injury.

Narrative review of ferroptosis in obesity

Ferroptosis: An important mechanism of disease mediated by the gut-liver-brain axis

Regulation of Ferroptosis in Obesity: Muscle Type-Specific Effects of Dietary Restriction and Exercise

Interaction between ferroptosis and TNF‐α: Impact in obesity‐related osteoporosis

Mitochondrial oxidative stress mediated Fe-induced ferroptosis via the NRF2-ARE pathway

The Potential Association of TFR1/SLC11A2/GPX4 with Ferroptosis in Mediating Lipid Metabolism Disorders in Atherosclerosis

Ferroptosis at the nexus of metabolism and metabolic diseases

Ferroptosis: Potential Targets and Emerging Roles in Pancreatic Diseases

Iron Overload in Hypothalamic AgRP Neurons Contributes to Obesity and Related Metabolic Disorders

Ferroptosis in life: To be or not to be

Ferroptosis: underlying mechanisms and involvement in neurodegenerative diseases

Ferroptosis: a new regulatory mechanism in neuropathic pain

High insulin inhibits ferroptosis and alleviates acute lung injury via LNC473-HIF1{alpha}-GPX4/FSP1 axis in obese mice

Epigenetic Regulation of Ferroptosis in Central Nervous System Diseases

Ferroptosis: Iron-mediated cell death linked to disease pathogenesis

Targeting ferroptosis in neuroimmune and neurodegenerative disorders for the development of novel therapeutics

Ferroptosis and metabolic syndrome and complications: association, mechanism, and translational applications